Welcome to the CPPE page of Venous Thromboembolism and embolism. We will introduce you to the resources that CPPE, and other organisations, provide around this topic. Thrombosis UK state that every 37 seconds someone in the western world dies from a VTE. While there are risk factors that pre-dispose people to VTE, it can affect anyone regardless their demographics. VTE is the number one cause of preventable deaths in hospital, as up to 60 percent of blood clots occur within 90 days of hospital discharge globally. England continues to achieve the 95 percent NHS contract threshold for risk assessing over 16s for VTE on admission, but we still have a long way to go. We as pharmacy professionals have a role to play by supporting people who have had a VTE with their medicines and by being a source of information, promoting adherence and reducing rates of recurrence. This page contains a collection of useful resources to cover the basics of VTE and embolism, and ultimately, improve the service and support you provide to people at risk or who have had a VTE.
This factsheet aims to refresh your knowledge of pulmonary embolism (PE) and provide you with links to appropriate further resources. It covers the definitions and risk factors for PE and deep vein thrombosis (DVT), the prevalence and incidence of PE and DVT; as well as causes, complications and management of PE and DVT.
This clinical knowledge summary provides information needed for an understanding of the diagnosis and management of deep vein thrombosis (DVT), while providing background information and practical tips for prescribing anticoagulants.
This clinical knowledge summary provides information needed for an understanding of the diagnosis and management pulmonary embolism (PE), whilst providing background information and practical tips for prescribing anticoagulants.
The aim of this piece of learning is to support you to become more confident with biochemistry results and managing medicines in relation to those results. We have a series of case studies on different topics to help put your learning into practice.
Learning Objectives:On completion of all aspects of this learning programme you should be able to:
This NICE guideline includes a collection of recommendations regarding diagnosis and management of venous thromboembolisms (VTEs). It includes a 3-page visual summary of the guidance.
This NICE pathway is an overview of the topic and may be useful if you would like to know more about strategies to reduce venous thromboembolism (VTE) risk in people who are in hospital. It also offers strategies to ensure people have the best experience of NHS services, such as tailoring healthcare services for each person, by knowing them as an individual and ensuring continuity of care and relationships upon discharge.
This is a guideline designed to inform healthcare professionals on all aspects of the use of warfarin. It details the appropriate use, and how to manage warfarin for people preparing for, and recovering from, surgical and dental procedures.
This resource provides some information about idarucizumab (the reversal agent for dabigatran). This is a useful resource for your practice, as some people will be concerned about the lack of an antidote for direct oral anticoagulants (DOACs), like there are for warfarin (vitamin K).
This resource provides some information about andexanet alfa (the reversal agent for apixaban and rivaroxaban).
This is a useful resource for your practice, as some people will be concerned about the lack of an antidote for direct oral anticoagulants (DOACs), like there are for warfarin (vitamin K).
The discussion around the use of direct oral anticoagulants (DOACs) in obesity is relevant for pharmacy professionals, as both healthcare professionals, and service users, may enquire about the effectiveness of DOACs versus warfarin - particularly in obesity.
Please help us improve our website by letting us know what you like and reporting anything that isn't quite right.